Clinical Trials Sponsored by Cell Pathways

Total 834 results

M.D. Anderson Cancer Center
Cell Pathways

Completed

Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients

Breast Neoplasms | Metastases, Neoplasm

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Completed

CP-461 for the Treatment of Crohn's Disease

Crohn's Disease

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Terminated

CP-461 in the Treatment of Patients With Advanced Melanoma

Malignant Melanoma

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Completed

Study Using CP-461 to Treat Advanced Prostate Cancer

Prostate Cancer

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Completed

Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
COMPASS Pathways

Recruiting

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Treatment Resistant Depression

United States, Spain, Ireland, United Kingdom, Canada
COMPASS Pathways

Completed

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

Treatment Resistant Depression

United States, Ireland
COMPASS Pathways

Completed

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (P-TRD)

Treatment Resistant Depression

United States, Netherlands, Ireland, Germany, United Kingdom, Canada, Czechia, Denmark, Portugal, Spain
COMPASS Pathways

Recruiting

Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Treatment Resistant Depression

United States
COMPASS Pathways

Recruiting

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

Major Depressive Disorder

United States
COMPASS Pathways

Recruiting

Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

Anorexia Nervosa

Ireland, United States, United Kingdom
COMPASS Pathways

Active, not recruiting

The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

Post Traumatic Stress Disorder

United States, United Kingdom
COMPASS Pathways

Completed

Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)

Treatment Resistant Depression

United States, Czechia, Netherlands, United Kingdom, Ireland
Pathway Genomics

Completed

Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease (H1000)

Neoplasms | Mutation

United States
Pathway Genomics

Terminated

Circulating Tumor DNA in Patients at High Risk for Lung Cancer

Lung Neoplasms | Lung Cancer | Adenocarcinoma of the Lung | Cancer of the Lung | Small Cell Carcinoma of the Lung | Non Small Cell Carcinoma of the Lung

United States
Pathway Genomics

Terminated

ctDNA in Patients With Thyroid Nodules

Thyroid Cancer | Thyroiditis | Thyroid Adenoma | Thyroid Nodules

United States
Pathway Genomics

Completed

Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy

Colon Cancer | Colon Adenomas | Colon Polyps

United States
Massachusetts General Hospital
COMPASS Pathways

Withdrawn

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

Treatment-Resistant Major Depressive Disorder

United States
Massachusetts General Hospital
COMPASS Pathways

Not yet recruiting

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

Major Depressive Disorder
Vigilant Biosciences, Inc.
Pearl Pathways

Completed

Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making

Oral Ulcer | Oropharyngeal Neoplasms | Leukoplakia, Oral | Tongue Neoplasms | Palatal Neoplasms | Lip Neoplasm | Gingival Neoplasms

United States
Pathway Therapeutics, Inc.

Completed

Study of PWT33597 Mesylate in Subjects With Advanced Malignancies

Malignancies

United States
Sheppard Pratt Health System
COMPASS Pathways

Active, not recruiting

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

Treatment Resistant Depression

United States
Sheppard Pratt Health System
COMPASS Pathways

Recruiting

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

Suicidal Ideation | Treatment Resistant Depression

United States
Sheppard Pratt Health System
COMPASS Pathways

Active, not recruiting

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

Treatment Resistant Depression

United States
Cell Genesys

Completed

Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)

Prostate Cancer
Cell Genesys

Completed

Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer)

Prostate Cancer
Cell Genesys

Completed

Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer

Prostate Cancer
Pathway Medical Technologies Inc.

Completed

A Study to Collect Intravascular Ultrasound Images Before and After Treatment With the Jetstream System

Peripheral Arterial Disease | Peripheral Vascular Disease

United States
Pathway Medical Technologies Inc.

Completed

The Pathway PVD Study for Percutaneous Peripheral Vascular Interventions

Peripheral Artery Disease
Cell Genesys

Terminated

Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

Prostate Cancer

United States, France, United Kingdom, Italy, Germany, Netherlands, Canada, Poland, Sweden, Belgium
Cell Genesys

Completed

Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

Acute Myelogenous Leukemia

United States
Cell Genesys

Terminated

Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer

Prostate Cancer

United States
Cell Genesys

Terminated

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

Prostate Cancer

United States, France, Belgium, Canada, United Kingdom, Sweden, Netherlands, Germany
Cell Genesys

Unknown

Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

Carcinoma, Transitional Cell | Bladder Neoplasms

United States, Canada
Cell Genesys

Completed

A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | Lung Cancer
Cell Genesys

Completed

Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine

Prostate Cancer

United States
Cell Genesys

Completed

Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma

Multiple Myeloma

United States
Cell Genesys

Completed

A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer | Nonresectable Pancreatic Cancer

United States
Cell Genesys

Completed

Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer

Prostate Cancer
University of California, San Diego
COMPASS Pathways

Completed

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

Anorexia Nervosa

United States
European Pathway Association
KU Leuven

Completed

Care Pathways for Benchmarking on Fragile Hip Fractures Rapid Recovery

Hip Fractures | Quality Improvement

Belgium
European Pathway Association
KU Leuven

Completed

Care Pathways for Colorectal Cancer Surgery (CP4GICAN)

Cancer

Belgium
CELL Technologies Inc.

Not yet recruiting

Bone Marrow Aspirate Concentrate (BMAC) Treatment for Knee Osteoarthritis (ACCELERATE3)

Musculoskeletal Diseases | Knee Osteoarthritis

Canada
Gamida Cell ltd

Completed

Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients

Patients Transplanted With NiCord/CordIn (Omidubicel)

United States, Singapore, Spain, Netherlands
Gamida Cell ltd

Active, not recruiting

Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Hematological Malignancies

United States
GC Cell Corporation

Completed

Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients

Hepatocellular Carcinoma

Korea, Republic of
Gamida Cell ltd

Completed

Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Hodgkin's Disease | Acute Myelogenous Leukemia (AML)

United States
Cell>Point LLC

Unknown

Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)

Coronary Artery Disease

United States
Cell>Point LLC

Active, not recruiting

A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer

Lung Cancer

United States
Cell Medica Ltd

Terminated

Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (CIVIC)

Lymphoma, Large B-Cell, Diffuse | Hodgkin Lymphoma | Post-transplant Lymphoproliferative Disorder

United States

Clinical Trials Sponsored by Cell Pathways

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations